South Chico Dialysis Center is a medicare approved dialysis facility center in Chico, California and it has 18 dialysis stations. It is located in Butte county at 2345 Forest Avenue, Chico, CA, 95928. You can reach out to the office of South Chico Dialysis Center at (530) 894-2180. This dialysis clinic is managed and/or owned by Davita. South Chico Dialysis Center has the following ownership type - Profit. It was first certified by medicare in August, 2004. The medicare id for this facility is 552530 and it accepts patients under medicare ESRD program.
| Name | South Chico Dialysis Center |
|---|---|
| Location | 2345 Forest Avenue, Chico, California |
| No. of Dialysis Stations | 18 |
| Medicare ID | 552530 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2345 Forest Avenue, Chico, California, 95928 | |
| (530) 894-2180 | |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
| NPI Number | 1245293356 |
| Organization Name | South Chico Dialysis Center |
| Doing Business As | Renal Treatment Centers California Inc |
| Address | 2345 Forest Ave Chico, California, 95928 |
| Phone Number | (530) 894-2180 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
| NPI Number | 1659889632 |
| Organization Name | Bidwell Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 966 East Ave Chico, California, 95926 |
| Phone Number | (530) 892-9937 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 28 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 54 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 449 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at South Chico Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 54 |
| Hypercalcemia patient months | 449 |
| Patients with Serumphosphor | 58 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 14 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 59 |
| Patient months included in arterial venous fistula and catheter summaries | 396 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 84 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 53 |
| Hospitalization Rate in facility | 228.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 386.8 |
| Hospitalization Rate: Lower Confidence Limit | 139.8 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at South Chico Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 33.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 44.1 |
| Readmission Rate: Lower Confidence Limit | 23.8 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at South Chico Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .6 (As Expected) |
| SIR: Upper Confidence Limit | 1.99 |
| SIR: Lower Confidence Limit | .1 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether South Chico Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 49 |
| Transfusion Rate in facility | 32.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 105.8 |
| Transfusion Rate: Lower Confidence Limit | 11.6 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at South Chico Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 241 |
| Mortality Rate in facility | 25.6 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 34.2 |
| Mortality Rate: Lower Confidence Limit | 18.7 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago
RAI Ceres Avenue, Chico Location: 3011 Ceres Avenue #125, Chico, California, 95973 Phone: (530) 343-5279 |
South Chico Dialysis Center Location: 2345 Forest Avenue, Chico, California, 95928 Phone: (530) 894-2180 |
News Archive
It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
Ingen Technologies, Inc., is an ISO Certified and FDA Registered medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company sells their patented and proprietary Oxyview and SMART Nasal Cannula along with their most recent released INGEN Pulse Oximeter. Today the company announced Proxy results and growth plans.
Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.
Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.
› Verified 5 days ago